Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian F Pollack

Showing results (231-240 of 308) with videos related to

Pageof 31
Sort By:
Neuro-Oncology|February 13, 2007
Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium reportIan F Pollack, Regina I Jakacki, Susan M Blaney, et al.
Pediatric Blood & Cancer|July 1, 2010
Mismatch repair deficiency is an uncommon mechanism of alkylator resistance in pediatric malignant gliomas: a report from the Children's Oncology GroupIan F Pollack, Ronald L Hamilton, Robert W Sobol, et al.
Neurosurgical Focus|April 1, 2021
Hydrocephalus treatment in patients with craniosynostosis: an analysis from the Hydrocephalus Clinical Research Network prospective registryChristopher M Bonfield, Chevis N Shannon, Ron W Reeder, et al.
Neuro-Oncology|April 17, 2025
A Phase 2 PBTC Study of Selumetinib for Recurrent/Progressive Pediatric Low-Grade Glioma: Strata 2, 5, and 6 with Long-term Outcomes on Strata 1, 3, and 4Jason Fangusaro, Arzu Onar-Thomas, Tina Young Poussaint, et al.
JAMA Oncology|July 22, 2021
Efficacy of Carboplatin and Isotretinoin in Children With High-risk Medulloblastoma: A Randomized Clinical Trial From the Children's Oncology GroupSarah E S Leary, Roger J Packer, Yimei Li, et al.
Neuro-Oncology|March 25, 2017
A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) studyAnuradha Banerjee, Regina I Jakacki, Arzu Onar-Thomas, et al.
Journal of Neurosurgery. Pediatrics|February 7, 2025
Reimagining durability of hydrocephalus treatment using conditional survivalAaron M Yengo-Kahn, John C Wellons, Hailey Jensen, et al.
Nature Cancer|February 5, 2022
The current landscape of immunotherapy for pediatric brain tumorsEugene I Hwang, Elias J Sayour, Catherine T Flores, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 2002
Preradiation chemotherapy in primary high-risk brainstem tumors: phase II study CCG-9941 of the Children's Cancer GroupMark T Jennings, Richard Sposto, James M Boyett, et al.
Neuro-Oncology|March 21, 2022
Corrigendum to: LTBK-01. Updates On The Phase Ii And Re-treatment Study Of AZD6244 (Selumetinib) For Children With Recurrent Or Refractory Pediatric Low Grade Glioma: A Pediatric Brain Tumor Consortium (PBTC) StudyJason R Fangusaro, Arzu Onar-Thomas, Tina Young Poussaint, et al.
Pageof 31

Showing results (231-240 of 308) with videos related to

Sort By:
Pageof 31
Neuro-Oncology|February 13, 2007
Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium reportIan F Pollack, Regina I Jakacki, Susan M Blaney, et al.
Pediatric Blood & Cancer|July 1, 2010
Mismatch repair deficiency is an uncommon mechanism of alkylator resistance in pediatric malignant gliomas: a report from the Children's Oncology GroupIan F Pollack, Ronald L Hamilton, Robert W Sobol, et al.
Neurosurgical Focus|April 1, 2021
Hydrocephalus treatment in patients with craniosynostosis: an analysis from the Hydrocephalus Clinical Research Network prospective registryChristopher M Bonfield, Chevis N Shannon, Ron W Reeder, et al.
Neuro-Oncology|April 17, 2025
A Phase 2 PBTC Study of Selumetinib for Recurrent/Progressive Pediatric Low-Grade Glioma: Strata 2, 5, and 6 with Long-term Outcomes on Strata 1, 3, and 4Jason Fangusaro, Arzu Onar-Thomas, Tina Young Poussaint, et al.
JAMA Oncology|July 22, 2021
Efficacy of Carboplatin and Isotretinoin in Children With High-risk Medulloblastoma: A Randomized Clinical Trial From the Children's Oncology GroupSarah E S Leary, Roger J Packer, Yimei Li, et al.
Neuro-Oncology|March 25, 2017
A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) studyAnuradha Banerjee, Regina I Jakacki, Arzu Onar-Thomas, et al.
Journal of Neurosurgery. Pediatrics|February 7, 2025
Reimagining durability of hydrocephalus treatment using conditional survivalAaron M Yengo-Kahn, John C Wellons, Hailey Jensen, et al.
Nature Cancer|February 5, 2022
The current landscape of immunotherapy for pediatric brain tumorsEugene I Hwang, Elias J Sayour, Catherine T Flores, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 2002
Preradiation chemotherapy in primary high-risk brainstem tumors: phase II study CCG-9941 of the Children's Cancer GroupMark T Jennings, Richard Sposto, James M Boyett, et al.
Neuro-Oncology|March 21, 2022
Corrigendum to: LTBK-01. Updates On The Phase Ii And Re-treatment Study Of AZD6244 (Selumetinib) For Children With Recurrent Or Refractory Pediatric Low Grade Glioma: A Pediatric Brain Tumor Consortium (PBTC) StudyJason R Fangusaro, Arzu Onar-Thomas, Tina Young Poussaint, et al.
Pageof 31